Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 22, 2015 23:11:31 GMT -5
that they were approached with offers for a buyout, this was sometime last year. However, the price was to low, I recall. If I am wrong please provide clarification, as I am unable to find this from previous presentations. I bring this up to discuss the possibility of buyout, and a possible bidding war which could insue. As Sanofi has the first crack at purchasing Afrezza, I would imagine some news soon than later in terms of even a small, yet greater than 5% investment in MNKD. While the weekly RXs dont astonish, there is the pleasure of a small and growing total. This cannot be ignored. Sanofi. Which is currently in the process of rearranging its structure, have Afrezza as a part of the "big" picture.
There was a post by "im_a_genius" over on the Yahzoo MB, he was previously, up to this point a strong supporter of MNKD and the SNY deal. While his current opinion has changed he still remains long. The point I want to discuss is that he states that Sanofi reps are not hungery enough, and it is much easier to push Toujeo. And while the two drugs are in completely different categories, he argues that the focus is on Toujeo, and not Afrezza. If this is the case, he continues with a solution, where MNKD leaves SNY, and finds a drug company with a "hungrier" sales force. One that helps Afrezza reach Blockbuster status quickly, burning shorts in their seats. If we were to go after a "hungrier" sales force, would SNY feel strongly enough about Afrezza, to counter other offers. Additionally, while Afrezza is a completely different approach to managing diabetes, it is extremely effective, correct. So why doesn't SNY step up with an ad campaign worthy of Afrezza's potential?
|
|
|
|
Post by charlespk on Jul 23, 2015 0:58:40 GMT -5
Al also said , " it will be an embarassment of riches " , and I believe in Al .
Al and Matt , we are ready, for you "to show us the money"
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 23, 2015 1:29:29 GMT -5
I believe it was Matt who made the embarassment of riches remark.
|
|
|
|
Post by babaoriley on Jul 23, 2015 2:12:22 GMT -5
george, a shift by MNKD away from Sanofi would be a mess of gigantic proportions. And I can't imagine another pharma wanting in that mess. If such a move would be announced, it would be "goodnight ladies" for many shareholders.
|
|
|
|
Post by bobb1234 on Jul 23, 2015 3:43:18 GMT -5
And I can't imagine another pharma wanting in that mess. If such a move would be announced, it would be "goodnight ladies" for many shareholders. Read more: mnkd.proboards.com/thread/3050/recall-al-saying#ixzz3ghajkfQM Please explain. Not sure I understand your view on another big pharma buyout. Although I think highly unlikely. |
|
|
|
Post by ezrasfund on Jul 23, 2015 7:45:48 GMT -5
There is no buyout in the works. The only comment by Al about selling the company that I recall was made at the 2014 annual shareholders' meeting. In the discussion after the meeting Al was asked about a buyout and replied that he was not trying to sell the company but was always open to offers,although none had been made. I believe someone on this board posted video of that comment.
Baba is right that any unraveling of the Sanofi deal would create an incredible mess. With 20/20 hindsight it is obvious that Sanofi has always been MannKind's primary partner, as during the trials Lantus was always used, and MNKD was saying things like "we are working with our potential partners to design trials," etc.
During partnership negotiations MNKD's main obstacle was to show Sanofi that they had other alternatives for partnership, and if there was going to be a buyout in the near term that would have been the time.
|
|
|
|
Post by mnholdem on Jul 23, 2015 9:46:33 GMT -5
I also remember Al joking around after being questioned about Merck as a partner. Al's comment was that someday, MannKind may be big enough to buy out Merck. To me, that sounds like someone who plans to grow the company rather than sell it.  |
|
|
|
Post by orlon on Jul 23, 2015 13:03:48 GMT -5
There is no buyout in the works. The only comment by Al about selling the company that I recall was made at the 2014 annual shareholders' meeting. In the discussion after the meeting Al was asked about a buyout and replied that he was not trying to sell the company but was always open to offers,although none had been made. I believe someone on this board posted video of that comment. Baba is right that any unraveling of the Sanofi deal would create an incredible mess. With 20/20 hindsight it is obvious that Sanofi has always been MannKind's primary partner, as during the trials Lantus was always used, and MNKD was saying things like "we are working with our potential partners to design trials," etc. During partnership negotiations MNKD's main obstacle was to show Sanofi that they had other alternatives for partnership, and if there was going to be a buyout in the near term that would have been the time. Sanofi has the first right of refusal to buy Mannkind under the current agreement. What would prevent Sanofi from buying out MNKD? The milestone payments etc would essentially flow back to Sanofi would they not? The company is reorganizing effective January 2016, which would make it a good opportunity for Sanofi. I am just saying anything is possible, and not being in the boardroom who knows what is being bounced around. |
|
|
|
Post by sportsrancho on Jul 23, 2015 15:16:40 GMT -5
And I can't imagine another pharma wanting in that mess. If such a move would be announced, it would be "goodnight ladies" for many shareholders. Read more: mnkd.proboards.com/thread/3050/recall-al-saying#ixzz3ghajkfQM Please explain. Not sure I understand your view on another big pharma buyout. Although I think highly unlikely. . It's switching partners IMO that would be a mess! SNY could buy us out if they met Al's price. Which like you said no one has done yet. Toujeo and Afrezza will be a great combo. Seems like that's SNY plan! Charles from YMB is on both and doing so well! |
|
